Tuesday, February 18, 2014

Biosensors Int'l -Can it get cheaper than this? (CIMB)

Biosensors Int'l
Current S$0.87
Target S$1.19
Can it get cheaper than this?

Biosensors posted results that were largely in line with our expectations. Its 3QFY14 core EPS made up 23% of our full-year forecast, while its 9M number was 72% of our FY14. We keep our below-consensus estimates unchanged. Likewise, our SOP-based target price remains intact. We reiterate our contrarian Add rating, which is premised on the instant success of product launches, regulatory approvals, and M&A accretion.


Results in line
9MFY14’s results did not surprised, coming in at 72% of our full-year forecast because of: 1) a 21% yoy decline in licensing revenue due to continued challenges in Japan, and 2) higher operating expenditure from SG&A arising from its costly brand-building exercise, though better cost measures have been put in place. At the moment, its overall gross margin for products (72%) in 3QFY14 is weak, primarily due to the burden of distribution activities in Japan for the Nobori stents, and its newly-acquired cardiac diagnostic business, both of which have lower gross profit margin contributions.

Same old issues
As with volume growth in the EMEA and APAC regions (in the double-digits, according to management), DES sales in China should improve significantly. However, we believe the persistent ASP weakness has led management to lower its FY14 revenue growth guidance to weak (from 15% previously), similar to forecasts. While there is not much room for improvement in licensing and royalty income in the next few quarters, it is pleasing to note that its initial direct sales penetration in Japan has been yielding positive results.

ADD rating maintained
BIG’s valuation has only priced in its near-term challenges, not a potential earnings lift from the commercialisation of new products in FY15. Other products gaining ground with various regulatory authorities and the soft launch of BioFreedom could become sources of excitement. Its new shareholder CITIC PE is expected to have a lot more say in the globalisation of BIG’s business and restructuring initiatives aimed at improving efficiency and profitability. We maintain our ADD rating.




Source/Extract/Excerpts/来源/转贴/摘录: CIMB-Research,
Publish date:13/02/14

No comments:

Post a Comment

Warren E. Buffett(沃伦•巴菲特)
Be fearful when others are greedy, and be greedy when others are fearful
别人贪婪时我恐惧, 别人恐惧时我贪婪
投资只需学好两门课: 一,是如何给企业估值,二,是如何看待股市波动
吉姆·罗杰斯(Jim Rogers)
“错过时机”胜于“搞错对象”:不会全军覆没!”
做自己熟悉的事,等到发现大好机会才投钱下去

乔治·索罗斯(George Soros)

“犯错误并没有什么好羞耻的,只有知错不改才是耻辱。”

如果操作过量,即使对市场判断正确,仍会一败涂地。

李驰(中国巴菲特)
高估期间, 卖对, 不卖也对, 买是错的。
低估期间, 买对, 不买也是对, 卖是错的。

Tan Teng Boo


There’s no such thing as defensive stocks.Every stock can be defensive depending on what price you pay for it and what value you get,
冷眼(冯时能)投资概念
“买股票就是买公司的股份,买股份就是与陌生人合股做生意”。
合股做生意,则公司股份的业绩高于一切,而股票的价值决定于盈利。
价值是本,价格是末,故公司比股市重要百倍。
曹仁超-香港股神/港股明灯
1.有智慧,不如趁势
2.止损不止盈
成功者所以成功,是因为不怕失败!失败者所以失败,是失败后不再尝试!
曾淵滄-散户明灯
每逢灾难就是机会,而是在灾难发生时贱价买股票,然后放在一边,耐性地等灾难结束
  • Selected Indexes 52 week range

  • Margin of Safety

    Investment Clock

    World's First Interactive Investment Clock